295 related articles for article (PubMed ID: 23791822)
1. Effect of thrombolysis with alteplase within 6 h of acute ischaemic stroke on long-term outcomes (the third International Stroke Trial [IST-3]): 18-month follow-up of a randomised controlled trial.
IST-3 collaborative group
Lancet Neurol; 2013 Aug; 12(8):768-76. PubMed ID: 23791822
[TBL] [Abstract][Full Text] [Related]
2. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial.
; Sandercock P; Wardlaw JM; Lindley RI; Dennis M; Cohen G; Murray G; Innes K; Venables G; Czlonkowska A; Kobayashi A; Ricci S; Murray V; Berge E; Slot KB; Hankey GJ; Correia M; Peeters A; Matz K; Lyrer P; Gubitz G; Phillips SJ; Arauz A
Lancet; 2012 Jun; 379(9834):2352-63. PubMed ID: 22632908
[TBL] [Abstract][Full Text] [Related]
3. Effects of alteplase on survival after ischaemic stroke (IST-3): 3 year follow-up of a randomised, controlled, open-label trial.
Berge E; Cohen G; Roaldsen MB; Lundström E; Isaksson E; Rudberg AS; Slot KB; Forbes J; Smith J; Drever J; Wardlaw JM; Lindley RI; Sandercock PA; Whiteley WN;
Lancet Neurol; 2016 Sep; 15(10):1028-34. PubMed ID: 27450474
[TBL] [Abstract][Full Text] [Related]
4. Association between brain imaging signs, early and late outcomes, and response to intravenous alteplase after acute ischaemic stroke in the third International Stroke Trial (IST-3): secondary analysis of a randomised controlled trial.
IST-3 collaborative group
Lancet Neurol; 2015 May; 14(5):485-96. PubMed ID: 25819484
[TBL] [Abstract][Full Text] [Related]
5. Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 trial.
Anderson CS; Huang Y; Lindley RI; Chen X; Arima H; Chen G; Li Q; Billot L; Delcourt C; Bath PM; Broderick JP; Demchuk AM; Donnan GA; Durham AC; Lavados PM; Lee TH; Levi C; Martins SO; Olavarria VV; Pandian JD; Parsons MW; Pontes-Neto OM; Ricci S; Sato S; Sharma VK; Silva F; Song L; Thang NH; Wardlaw JM; Wang JG; Wang X; Woodward M; Chalmers J; Robinson TG;
Lancet; 2019 Mar; 393(10174):877-888. PubMed ID: 30739745
[TBL] [Abstract][Full Text] [Related]
6. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis.
Wardlaw JM; Murray V; Berge E; del Zoppo G; Sandercock P; Lindley RL; Cohen G
Lancet; 2012 Jun; 379(9834):2364-72. PubMed ID: 22632907
[TBL] [Abstract][Full Text] [Related]
7. Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study.
Huang X; Cheripelli BK; Lloyd SM; Kalladka D; Moreton FC; Siddiqui A; Ford I; Muir KW
Lancet Neurol; 2015 Apr; 14(4):368-76. PubMed ID: 25726502
[TBL] [Abstract][Full Text] [Related]
8. Thrombolysis for acute ischaemic stroke with alteplase in an Asian population: results of the multicenter, multinational Safe Implementation of Thrombolysis in Stroke-Non-European Union World (SITS-NEW).
Rha JH; Shrivastava VP; Wang Y; Lee KE; Ahmed N; Bluhmki E; Hermansson K; Wahlgren N;
Int J Stroke; 2014 Oct; 9 Suppl A100():93-101. PubMed ID: 22988894
[TBL] [Abstract][Full Text] [Related]
9. Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis.
Whiteley WN; Emberson J; Lees KR; Blackwell L; Albers G; Bluhmki E; Brott T; Cohen G; Davis S; Donnan G; Grotta J; Howard G; Kaste M; Koga M; von Kummer R; Lansberg MG; Lindley RI; Lyden P; Olivot JM; Parsons M; Toni D; Toyoda K; Wahlgren N; Wardlaw J; Del Zoppo GJ; Sandercock P; Hacke W; Baigent C;
Lancet Neurol; 2016 Aug; 15(9):925-933. PubMed ID: 27289487
[TBL] [Abstract][Full Text] [Related]
10. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials.
Emberson J; Lees KR; Lyden P; Blackwell L; Albers G; Bluhmki E; Brott T; Cohen G; Davis S; Donnan G; Grotta J; Howard G; Kaste M; Koga M; von Kummer R; Lansberg M; Lindley RI; Murray G; Olivot JM; Parsons M; Tilley B; Toni D; Toyoda K; Wahlgren N; Wardlaw J; Whiteley W; del Zoppo GJ; Baigent C; Sandercock P; Hacke W;
Lancet; 2014 Nov; 384(9958):1929-35. PubMed ID: 25106063
[TBL] [Abstract][Full Text] [Related]
11. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial.
Menon BK; Buck BH; Singh N; Deschaintre Y; Almekhlafi MA; Coutts SB; Thirunavukkarasu S; Khosravani H; Appireddy R; Moreau F; Gubitz G; Tkach A; Catanese L; Dowlatshahi D; Medvedev G; Mandzia J; Pikula A; Shankar J; Williams H; Field TS; Manosalva A; Siddiqui M; Zafar A; Imoukhuede O; Hunter G; Demchuk AM; Mishra S; Gioia LC; Jalini S; Cayer C; Phillips S; Elamin E; Shoamanesh A; Subramaniam S; Kate M; Jacquin G; Camden MC; Benali F; Alhabli I; Bala F; Horn M; Stotts G; Hill MD; Gladstone DJ; Poppe A; Sehgal A; Zhang Q; Lethebe BC; Doram C; Ademola A; Shamy M; Kenney C; Sajobi TT; Swartz RH;
Lancet; 2022 Jul; 400(10347):161-169. PubMed ID: 35779553
[TBL] [Abstract][Full Text] [Related]
12. Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial.
Zinkstok SM; Roos YB;
Lancet; 2012 Aug; 380(9843):731-7. PubMed ID: 22748820
[TBL] [Abstract][Full Text] [Related]
13. Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial.
Wang Y; Li S; Pan Y; Li H; Parsons MW; Campbell BCV; Schwamm LH; Fisher M; Che F; Dai H; Li D; Li R; Wang J; Wang Y; Zhao X; Li Z; Zheng H; Xiong Y; Meng X;
Lancet; 2023 Feb; 401(10377):645-654. PubMed ID: 36774935
[TBL] [Abstract][Full Text] [Related]
14. Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial.
Logallo N; Novotny V; Assmus J; Kvistad CE; Alteheld L; Rønning OM; Thommessen B; Amthor KF; Ihle-Hansen H; Kurz M; Tobro H; Kaur K; Stankiewicz M; Carlsson M; Morsund Å; Idicula T; Aamodt AH; Lund C; Næss H; Waje-Andreassen U; Thomassen L
Lancet Neurol; 2017 Oct; 16(10):781-788. PubMed ID: 28780236
[TBL] [Abstract][Full Text] [Related]
15. Effect of alteplase within 6 hours of acute ischemic stroke on all-cause mortality (third International Stroke Trial).
Whiteley WN; Thompson D; Murray G; Cohen G; Lindley RI; Wardlaw J; Sandercock P;
Stroke; 2014 Dec; 45(12):3612-7. PubMed ID: 25370587
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of sonothrombolysis for acute ischaemic stroke: a multicentre, double-blind, phase 3, randomised controlled trial.
Alexandrov AV; Köhrmann M; Soinne L; Tsivgoulis G; Barreto AD; Demchuk AM; Sharma VK; Mikulik R; Muir KW; Brandt G; Alleman J; Grotta JC; Levi CR; Molina CA; Saqqur M; Mavridis D; Psaltopoulou T; Vosko M; Fiebach JB; Mandava P; Kent TA; Alexandrov AW; Schellinger PD;
Lancet Neurol; 2019 Apr; 18(4):338-347. PubMed ID: 30878103
[TBL] [Abstract][Full Text] [Related]
17. Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial.
Kvistad CE; Næss H; Helleberg BH; Idicula T; Hagberg G; Nordby LM; Jenssen KN; Tobro H; Rörholt DM; Kaur K; Eltoft A; Evensen K; Haasz J; Singaravel G; Fromm A; Thomassen L
Lancet Neurol; 2022 Jun; 21(6):511-519. PubMed ID: 35525250
[TBL] [Abstract][Full Text] [Related]
18. Alteplase for acute ischemic stroke: outcomes by clinically important subgroups in the Third International Stroke Trial.
Lindley RI; Wardlaw JM; Whiteley WN; Cohen G; Blackwell L; Murray GD; Sandercock PA;
Stroke; 2015 Mar; 46(3):746-56. PubMed ID: 25613308
[TBL] [Abstract][Full Text] [Related]
19. Effect of alteplase on the CT hyperdense artery sign and outcome after ischemic stroke.
Mair G; von Kummer R; Morris Z; von Heijne A; Bradey N; Cala L; Peeters A; Farrall AJ; Adami A; Potter G; Cohen G; Sandercock PA; Lindley RI; Wardlaw JM;
Neurology; 2016 Jan; 86(2):118-25. PubMed ID: 26658907
[TBL] [Abstract][Full Text] [Related]
20. Extending thrombolysis to 4·5-9 h and wake-up stroke using perfusion imaging: a systematic review and meta-analysis of individual patient data.
Campbell BCV; Ma H; Ringleb PA; Parsons MW; Churilov L; Bendszus M; Levi CR; Hsu C; Kleinig TJ; Fatar M; Leys D; Molina C; Wijeratne T; Curtze S; Dewey HM; Barber PA; Butcher KS; De Silva DA; Bladin CF; Yassi N; Pfaff JAR; Sharma G; Bivard A; Desmond PM; Schwab S; Schellinger PD; Yan B; Mitchell PJ; Serena J; Toni D; Thijs V; Hacke W; Davis SM; Donnan GA;
Lancet; 2019 Jul; 394(10193):139-147. PubMed ID: 31128925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
